Alopecia Treatment Market, By Drug Class (Corticosteroids, 5 AR Inhibitors, Vasodilators, Others), By Disease Type (Alopecia Areata, Androgenic Alopecia, Traction Alopecia, Others), By Route of Administration (Topical, Oral, Injectable Topical application), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI1847

Pages :193

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Alopecia Treatment Market - Drivers

Increasing product approvals for the treatment of alopecia: The increasing product approvals for the treatment of alopecia is expected to propel growth of the global alopecia treatment market over the forecast period. For instance, in June 2023, Pfizer Inc., a multinational biopharmaceutical corporation, announced that the U.S. Food and Drug Administration (FDA) had approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the U.S. FDA for adolescents (12+) with severe alopecia areata.
Increasing research and development activities for the treatment of alopecia by market players: Increasing research and development activities for the treatment of alopecia by market players is expected to drive the global alopecia treatment market growth over the forecast period. For instance, in March 2023, OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced that it had received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021, a treatment for androgenic alopecia, also known as male-pattern baldness.

Figure 2. Global Alopecia Treatment Market Share (%), By Region, 2023

Alopecia Treatment Market Report Coverage

Restraints & Challenges:

Hold On Clinical Trial

Global Alopecia Treatment Market: Restraint

Hold on clinical trial for alopecia treatment: Hold on clinical trials for the treatment of alopecia treatment is expected to hinder the market growth over the forecast period. For instance, in May 2023, Sun Pharmaceutical Industries Ltd. is a global specialty generic pharmaceutical company stated that the U.S. Food and Drug Administration (U.S. FDA) had hold study of 12 mg BID (twice a day) dose of deuruxolitinib on due to thrombotic events. The company said that it conducted a call with the drug regulator regarding a pulmonary embolism in one of the long-term Open Label Extension (OLE) studies. The company requires that the subjects that are currently on the dose in the OLE studies to be discontinued. The drug is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2 that is being studied for the treatment of alopecia areata.
Counterbalances: Cure for alopecia treatment is being done by continuous clinical trials that are safe and effective drugs, and therapies. So, trials need to be done on continuous basis without creating any hold on it, for proper carrying out of the trials.